Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
EVE Health Group Limited ( (AU:EVE) ) has shared an update.
EVE Health Group Limited has entered into a national prescribing agreement with TeleDocs Clinic for its oral soluble film for erectile dysfunction and gummy formulation for dysmenorrhea. This strategic partnership will enable EVE to leverage TeleDocs’ extensive network of over 3,500 pharmacies across Australia, enhancing product launch plans and patient access ahead of regulatory approvals. The collaboration will also involve practitioner education, digital integration, and promotional support, positioning EVE for a successful national rollout of its products.
More about EVE Health Group Limited
EVE Health Group (ASX: EVE) is an Australian-based health company that develops and commercializes evidence-based wellness and pharmaceutical products. Through its subsidiaries, Meluka Australia and Nextract, EVE delivers science-led innovations designed to support consumer and practitioner health across retail, pharmacy, and clinical channels.
Average Trading Volume: 1,169,596
Technical Sentiment Signal: Sell
Current Market Cap: A$8.59M
Learn more about EVE stock on TipRanks’ Stock Analysis page.